Ratings by Lucid Capital Markets (Elemer Piros)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/30/2026 | Quince Therapeutics Inc. | QNCX | Downgrade | Sell (Buy) |
0.27 (0.10) |
-62.96% | Details | |
| 12/17/2025 | VistaGen Therapeutics | VTGN | Downgrade | Neutral (Buy) |
4.36 (0.61) |
-86.01% | Details | |
| 12/9/2025 | XOMA, Ltd. | XOMA | New Coverage | Buy (N/A) |
30.49 (25.98) |
-14.79% | Details | |
| 11/24/2025 | Passage Bio Inc. | PASG | New Coverage | Buy (N/A) |
7.74 (8.40) |
8.53% | Details | |
| 11/12/2025 | Unicycive Therapeutics | UNCY | Maintain | Buy (N/A) |
|
Details | ||
| 10/21/2025 | Neuphoria Therapeutics Inc. | NEUP | Downgrade | Neutral (Buy) |
15.40 (4.32) |
-71.95% | Details | |
| 10/6/2025 | Cassava Sciences | SAVA | New Coverage | Buy (N/A) |
3.63 (2.03) |
-44.08% | Details | |
| 10/6/2025 | Cassava Sciences | SAVA | New Coverage | Buy (N/A) |
3.63 (3.63) |
0% | Details | |
| 9/30/2025 | Ocugen, Inc. | OCGN | New Coverage | Buy (N/A) |
1.45 (1.61) |
11.03% | Details | |
| 9/22/2025 | Coya Therapeutics | COYA | Maintain | Buy (N/A) |
|
Details | ||
| 8/13/2025 | Ovid Therapeutics Inc | OVID | New Coverage | Buy (N/A) |
0.55 (1.91) |
247.27% | Details | |
| 7/31/2025 | OKYO Pharma Ltd. | OKYO | New Coverage | Buy (N/A) |
2.51 (1.66) |
-33.86% | Details | |
| 7/22/2025 | Tiziana Life Sciences | TLSA | New Coverage | Buy (N/A) |
1.62 (1.39) |
-14.2% | Details | |
| 7/1/2025 | INmune Bio Inc. | INMB | Downgrade | Neutral (Buy) |
5.33 (1.33) |
-75.05% | Details | |
| 6/6/2025 | Cybin Inc. | CYBN | New Coverage | Buy (N/A) |
8.82 (8.28) |
-6.12% | Details | |
| 6/6/2025 | atai Life Sciences N.V | ATAI | New Coverage | Buy (N/A) |
2.48 (3.39) |
36.69% | Details | |
| 6/4/2025 | Unicycive Therapeutics | UNCY | New Coverage | Buy (N/A) |
0.76 (6.59) |
767.11% | Details | |
| 6/4/2025 | INmune Bio Inc. | INMB | New Coverage | Buy (N/A) |
7.27 (5.33) |
-26.69% | Details |
